BioMimetix Pharmaceutical

What BioMimetix Pharmaceutical does

BioMimetix Pharmaceutical is a privately held biopharmaceutical company founded in 2011 and headquartered in Greenwood Village, Colorado, with a headcount of 1–10 employees. The company develops therapeutic compounds targeting disease states including radiation toxicity and, more specifically, glioblastoma multiforme (GBM), a Grade IV malignant brain tumor with poor prognosis and limited treatment options. It is identified in DelveInsight's 2026 pipeline report as one of more than 200 entities advancing drug candidates in the glioblastoma treatment space, although no named product candidates or pipeline assets are disclosed in available sources.

The company's revenue model, pricing, customer base, and core technology are not disclosed in the source data, and its public website (biomimetixpharma.com) was not accessible at the time of data collection, returning only a verification/loading page. No patents, partnerships, distribution channels, marketing channels, regulatory milestones, or management team beyond CEO James D. Crapo are documented. Capital formation history shows a single $2.0 million funding round in July 2011 with no subsequent raises disclosed, indicating an early-stage or dormant posture relative to typical GBM-development peers. No AI/ML capabilities, integrations, or technology partnerships are referenced.

The business model cannot be characterized as commercial; the company operates as a preclinical or early-stage therapeutic developer dependent on capital markets and/or strategic partnerships for advancement. There are no disclosed licensing agreements, government grants, or commercial revenue. Investors and lead investor from the 2011 round remain undisclosed, and there is no evidence of institutional backing, M&A activity, or leadership turnover since inception.

Name

BioMimetix Pharmaceutical

Website

https://biomimetixpharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

BioMimetix Pharmaceutical is a privately held, early-stage biopharmaceutical company founded in 2011 that develops therapeutic compounds targeting radiation toxicity and glioblastoma multiforme (GBM) brain cancer.

Ownership category

akta.pro rank

Headquarters

HQ city

Greenwood Village

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

BioMimetix Pharmaceutical develops novel therapeutic compounds intended for the treatment of glioblastoma multiforme (GBM), a highly malignant Grade IV brain tumor with poor prognosis and limited effective treatment options, as well as for conditions such as radiation toxicity. The company operates as an early-stage biopharmaceutical research and development organization building a pipeline of proprietary therapies in the oncology and radiation countermeasure space.

Product overview

BioMimetix Pharmaceutical is a biopharmaceutical company developing novel therapies for glioblastoma (GBM), a highly malignant Grade IV brain tumor. The company is one of over 200 companies advancing pipeline drugs in the glioblastoma treatment space, as identified in DelveInsight's 2026 pipeline report. No specific named products or pipeline candidates are identified in the available source data.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Direct peers

• Kintara Therapeutics: Kintara Therapeutics (formerly DelMar Pharmaceuticals) develops therapeutics for GBM, with lead asset VAL-083 in clinical development. It is one of the most direct comparables to BioMimetix given its pure-play focus on glioblastoma multiforme.
• Diffusion Pharmaceuticals: Diffusion Pharmaceuticals develops small-molecule oxygen therapeutics, including trans-sodium crocetinate for GBM. Its GBM-focused clinical program and small-cap public status make it a directly comparable peer in indication and modality.
• DNAtrix: DNAtrix develops oncolytic virus immunotherapies for GBM, including DNX-2401. It is a clinical-stage peer directly attacking glioblastoma with a novel modality — comparable therapeutic focus if not technology class.
• Mustang Bio: Mustang Bio is a clinical-stage cell and gene therapy company with programs in GBM (MB-101, an IL13Rα2-targeting CAR-T). It is a directly comparable clinical-stage peer pursuing novel modalities for glioblastoma.
• Orbus Therapeutics: Orbus Therapeutics is a privately held clinical-stage company developing eflornithine (DFMO) for recurrent GBM. It is a closely comparable small-cap, private, indication-matched peer.

Broad incumbents

• Novocure: Novocure commercializes Tumor Treating Fields (Optune) as an approved therapy for newly diagnosed and recurrent GBM. As a profitable, FDA-approved GBM specialist, it represents the established incumbent benchmark in the same indication BioMimetix targets.
• Bristol-Myers Squibb: BMS markets Opdivo (nivolumab) and has studied it in GBM, making it a broad oncology incumbent with active interest in the glioblastoma space. It represents both a competitor and a potential acquirer for small GBM-focused biotechs.
• Merck & Co. Merck's Keytruda (pembrolizumab) has been investigated in GBM and the company remains a major oncology incumbent. Comparable as a large pharma peer with strategic interest in the same indication.

Emerging players

• Karyopharm Therapeutics: Karyopharm develops selinexor and has explored its use in GBM. It is a comparable emerging oncology player with partial overlap in therapeutic area and clinical-stage maturity.

Regional players

• Emcure Pharmaceuticals: Emcure is a global pharmaceutical manufacturer with presence in oncology and CNS therapeutics. It is relevant as a regional/international peer with exposure to specialty pharmaceutical manufacturing relevant to BioMimetix's compound-development focus.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/biomimetix

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMimetix Pharmaceutical